Key facts
Bonum Therapeutics, Inc.
New Form D on file · 2021-12-22 · the record
What the record says
Each marker is one filing. The larger marker is the filing this page is about.
Company officers on record
John Mulligan is named as Executive Officer and Director and Promoter on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 22 December 2021, one of 7 people that filing names.
John McKearn is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 22 December 2021, one of 7 people that filing names.
Monique Schiersing is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 22 December 2021, one of 7 people that filing names.
Nicholas Walrod is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 22 December 2021, one of 7 people that filing names.
Karl Handelsman is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 22 December 2021, one of 7 people that filing names.
Diane Hollenbaugh is named as Executive Officer on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 22 December 2021, one of 7 people that filing names.
Neela Patel is named as Executive Officer on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 22 December 2021, one of 7 people that filing names.
7 people named on the filing — 3 holding an executive role and 4 as directors only.
Named as of the 2021-12-22 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 7 people named on the filing — 3 holding an executive role and 4 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
Want the whole picture on Bonum Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bonum Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bonum Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Bonum Therapeutics, Inc.
- Source Check — verify John Mulligan's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with John Mulligan for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Bonum Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Bonum Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.